D. Nuyten

发表

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

M. J. van de Vijver, J. Bergh, S. Fox, 2006, Journal of the National Cancer Institute.

Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.

Howard Y. Chang, Yudong D. He, R. Tibshirani, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Lung metastasis genes couple breast tumor size and metastatic spread

H. Ishwaran, M. J. van de Vijver, B. Kreike, 2007, Proceedings of the National Academy of Sciences.

Genetic regulators of large-scale transcriptional signatures in cancer

Howard Y. Chang, H. Horlings, M. Vijver, 2006, Nature Genetics.

Concordance among Gene-Expression – Based Predictors for Breast Cancer

A. Nobel, C. Fan, C. Perou, 2011 .

Validation of 70-gene prognosis signature in node-negative breast cancer

A. Hart, J. Peterse, A. Glas, 2009, Breast Cancer Research and Treatment.

Revealing targeted therapy for human cancer by gene module maps.

Howard Y. Chang, A. Regev, M. J. van de Vijver, 2008, Cancer research.

Using microarray analysis as a prognostic and predictive tool in oncology: focus on breast cancer and normal tissue toxicity.

M. J. van de Vijver, D. Nuyten, 2008, Seminars in radiation oncology.

Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers

Trevor Hastie, Michael T Longaker, Edwin H Rodriguez, 2006, PLoS medicine.

Determination of Stromal Signatures in Breast Carcinoma

Tina Hernandez-Boussard, Kelli Montgomery, Robert B West, 2005, PLoS biology.

Imaging , Diagnosis , Prognosis Clinical Cancer Research Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients

Marcel J T Reinders, Carmen Lai, Christiaan Klijn, 2010 .

Characterization of heterotypic interaction effects in vitro to deconvolute global gene expression profiles in cancer

Trevor Hastie, T. Hastie, P. Brown, 2007, Genome Biology.

Gene Expression Programs of Human Smooth Muscle Cells: Tissue-Specific Differentiation and Prognostic Significance in Breast Cancers

T. Hastie, P. Brown, Sayan Mukherjee, 2007, PLoS genetics.

Phase II trial of the dual IGF-1R/IR inhibitor BMS-754807 with or without letrozole in aromatase inhibitor-resistant breast cancer.

A. Wolff, D. Nuyten, F. Huang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

From nanotechnology to nanomedicine: applications to cancer research.

E. Finot, C. Evelo, D. Nuyten, 2010, Current molecular medicine.

An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer

Hemant Ishwaran, Taewon Yoon, Yudi Pawitan, 2008, Proceedings of the National Academy of Sciences.

A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

M. Vijver, B. Gusterson, N. Salomonis, 2009, Journal of Mammary Gland Biology and Neoplasia.

The macrophage-stimulating protein pathway promotes metastasis in a mouse model for breast cancer and predicts poor prognosis in humans

Bruce H. Hasegawa, Alana L. Welm, M. J. van de Vijver, 2007, Proceedings of the National Academy of Sciences.

Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients

M. J. van de Vijver, H. Bartelink, B. Kreike, 2009, Clinical Cancer Research.

Predicting a local recurrence after breast-conserving therapy by gene expression profiling

Howard Y. Chang, P. Brown, M. J. van de Vijver, 2006, Breast Cancer Research.

Gene expression signatures to predict the development of metastasis in breast cancer.

M. J. van de Vijver, D. Nuyten, 2006, Breast disease.

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy

D. Nuyten, K. Chin, V. Chand, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of supervised gene signatures of early hypoxia on patient survival.

Glenn Fung, Balaji Krishnapuram, Philippe Lambin, 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

W. Hayes, D. Nuyten, J. Marshall, 2011, British Journal of Cancer.

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

M. J. van de Vijver, S. Linn, D. Nuyten, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Mouse Mammary Gland Involution mRNA Signature Identifies Biological Pathways Potentially Associated with Breast Cancer Metastasis

M. Vijver, B. Gusterson, N. Salomonis, 2009, Journal of Mammary Gland Biology and Neoplasia.

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

G. Jayson, M. Sawyer, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

First in human (FIH) study of an OX40 agonist monoclonal antibody (mAb) PF-04518600 (PF-8600) in adult patients (pts) with select advanced solid tumors: Preliminary safety and pharmacokinetic (PK)/pharmacodynamic results.

D. Nuyten, A. El-Khoueiry, O. Hamid, 2016 .

Gene expression profiling to predict outcome after chemoradiation in head and neck cancer.

Frank J P Hoebers, D. Atsma, F. Hoebers, 2007, International journal of radiation oncology, biology, physics.

Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.

Trevor Hastie, Howard Y. Chang, Howard Y Chang, 2008, European journal of cancer.

Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types

P Lambin, B. Krishnapuram, P. Lambin, 2008, British Journal of Cancer.

UvA-DARE ( Digital Academic Repository ) Hypothesis driven gene expression profiling in breast cancer

Howard Y. Chang, A. Hart, H. Bartelink, 2010 .

UvA-DARE ( Digital Academic Repository ) Who needs adjuvant systemic treatment ? Predicting prognosis in node-negative breast cancer ; from bench to bedside

S. Linn, D. Nuyten, J. Wesseling, 2009 .

ARC-7: Randomized phase 2 study of domvanalimab + zimberelimab ± etrumadenant versus zimberelimab in first-line, metastatic, PD-L1-high non-small cell lung cancer (NSCLC).

Melissa L. Johnson, D. Nuyten, Kang-Yun Lee, 2022, Journal of Clinical Oncology.

The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.

B. Kreike, J. Ogink, D. Nuyten, 2008, Cancer research.

Molecular profiles of progesterone receptor loss in human breast tumors

Adrian V. Lee, S. Hilsenbeck, R. Schiff, 2009, Breast Cancer Research and Treatment.

Gene Expression Pro fi ling in Breast Cancer : Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

C. Sotiriou, S. Loi, B. Haibe-Kains, 2006 .

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

M. J. van de Vijver, C. Sotiriou, S. Loi, 2006, Journal of the National Cancer Institute.

71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and PK/PD results

D. Nuyten, R. Ferris, R. Mehra, 2020 .

Predicting a local recurrence after breast-conserving therapy by gene expression profiling

Howard Y. Chang, M. J. van de Vijver, H. Bartelink, 2006, Breast Cancer Research.

Concordance among gene-expression-based predictors for breast cancer.

A. Nobel, C. Fan, C. Perou, 2006, The New England journal of medicine.

Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification.

Howard Y. Chang, T. Hastie, M. J. van de Vijver, 2008, European journal of cancer.

Avelumab: clinical trial innovation and collaboration to advance anti-PD-L1 immunotherapy

D. Nuyten, J. Soria, K. Chin, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.

S. Linn, D. Nuyten, J. Wesseling, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.